Court Finds Advanced Cell Diagnostics Patents Invalid in Lawsuit with Molecular Instruments
24 Abril 2024 - 11:00AM
Business Wire
Molecular Instruments, Inc. announced today that the Patents
Court of the High Court of England and Wales has found two patents
owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group
company) to be invalid.
In a 2022 lawsuit filed in the United Kingdom (proceedings no.
HP-2022-000026), Advanced Cell Diagnostics alleged that Molecular
Instruments’ HCR™ RNA-ISH technology infringes European Patents
(UK) 2,500,439 and 1,910,572. The Court has rejected that claim
ruling that both patents are invalid
(https://caselaw.nationalarchives.gov.uk/ewhc/pat/2024/898) with
Mr. Justice Meade finding that Molecular Instruments' primary
evidence (on invalidity) is "really overwhelming in this case."
“Our goal is to empower biologists, bioengineers, drug
developers, and diagnostics developers by providing them with
next-generation molecular tools that enable breakthroughs in their
projects,” said Dr. Harry Choi, CEO of Molecular Instruments. “We
felt compelled to fight this lawsuit to protect the ability of our
customers to continue their research, as many customers working in
challenging imaging settings cannot perform their experiments with
any other technology. This judgment in our favor ensures that UK
researchers will not be denied access to our game-changing HCR™
imaging platform.”
About the HCR™ imaging platform
HCR™ RNA in situ hybridization (RNA-ISH) leverages dynamic
nanotechnology to enable small amplification components to first
penetrate a biological sample without interacting and then
autonomously grow bright amplification polymers at the site of RNA
targets within the sample. This unique combination of properties
enables automated chromogenic and fluorescent HCR™ RNA-ISH
workflows to be entirely protease-free, preserving sample
morphology and protein target integrity for native compatibility
with existing immunohistochemistry (IHC)/immunofluorescence (IF)
assays. Likewise, manual fluorescent HCR™ RNA-ISH assays offer
unmatched performance, versatility, and robustness in samples of
all varieties including whole-mount vertebrate embryos,
multi-species environmental samples, thick brain slices, and
ultrathick samples up to 1 cm.
About Molecular Instruments
Molecular Instruments® (www.molecularinstruments.com) develops
and synthesizes molecular kits powered by the breakthrough HCR™
imaging platform for applications in academic research, drug
development, synthetic biology, and clinical pathology and
diagnostics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424629037/en/
media@molecularinstruments.com Joyce Yoo